Nanovi submits cancer biomarker for marketing approval in the US

Danish firm Nanovi has submitted its leading product, a biomarker for cancer therapies, for approval on the world’s biggest cancer market, where it has the potential to break new ground, says CEO Jesper Boysen.

Jesper Boysen, CEO of Nanovi | Photo: Nanovi / PR

Danish medtech firm Nanovi, whose chair of the board is Ambu heir Simon Hesse Hoffmann, has reached one of the bigger milestones in its history, which began in 2012 when the company was spun out from the Technical University of Denmark, DTU.

On Monday, the company announced it has submitted Bioxmark, a novel liquid soft tissue marker designed to be used in radiation therapy (RT) for multiple cancer types, for approval with the US Food and Drug Administration (FDA).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs